Ontada Signs Strategic Agreement with Merck to Facilitate the Development of Data-Driven Insights to Impact Quality of Cancer Care

Agreement Centered around the Identification and Development of Tangible Insights, Leveraging Real-World Data Best Practices

OntadaTM, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care. Ontada and Merck’s combined experience and expertise can help enable the confidence, acceptance, and ultimately impact of RWE on the quality of patient care.

Recommended AI News: HashCash to Build DeFi Lending Platforms in Collaboration Kong-Based With Hong Bank

“We look forward to working with Ontada on our shared purpose of improving the lives of patients with cancer.”

Susan Shiff, PhD, president of Ontada, shared, “Building on McKesson’s long history in community oncology, Ontada is uniquely positioned to advance cancer care by enabling collaboration between life sciences companies and oncology providers. With data insights from greater than two million records available for research and more than 2,000 oncology providers, Ontada helps life sciences companies like Merck leverage real-world data (RWD) and evidence-based insights at the point of care to accelerate innovation and improve cancer therapy.”

As part of the agreement, Merck and Ontada can collaborate on RWD studies to explore new scientific evidence, advanced methods development, and assessment of efficiency in cancer care.

Recommended AI News: Meshh Announces Channel Partnership With AI-Powered Sponsorship Analytics Platform Relo Metrics

“Merck is focused on bringing excellence to RWE generation by advancing methods and applying rigorous methods to gain RWD based insights,” said Ravinder Dhawan, PhD, Vice President and Head, Center for Observational and Real-World Evidence (CORE), Merck Research Laboratories. “We look forward to working with Ontada on our shared purpose of improving the lives of patients with cancer.”

“The patients we serve depend on strong relationships between oncology insights leaders like Ontada, life science innovators like Merck, and oncology providers,” said Dr. Michael Seiden, MD, PhD, president, The US Oncology Network. “RWD studies build on the body of evidence that oncology providers use in their treatment decision making, and innovation depends on all of us working together to achieve continued improvements in patient outcomes.”

Ontada combines real-world data and research capabilities, targeted channels to connect life sciences and providers for education and engagement, and a leading suite of technologies for oncology clinicians – including the iKnowMed℠ electronic health record system and Clear Value Plus℠ regimen support tool – with the reach of The US Oncology Network, supported by McKesson.

Recommended AI News: Amazon Announces Two New Cybersecurity Initiatives Aimed To Protect Organizations and Individuals